Preferred Label : brentuximab vedotin;

UMLS semantic type : T129 - Immunologic Factor;

Is substance : O;

Détails


Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :


https://www.ema.europa.eu/medicines/human/EPAR/Adcetris
2012
false
United Kingdom
French
English
Systemic Anaplastic Large Cell Lymphoma
CD30-Positive Neoplastic Cells Present
Recurrent Adult Hodgkin Lymphoma
Refractory Hodgkin Lymphoma
brentuximab vedotin
brentuximab vedotin
drug approval
treatment outcome
immunoconjugates
immunoconjugates
infusions, intravenous
orphan drug production
adult
hodgkin disease
hodgkin disease
Ki-1 Antigen
recurrence
antineoplastic agents
antineoplastic agents
lymphoma, large-cell, anaplastic
summary of product characteristics
package leaflet
drug evaluation
syndication feed
antibodies, monoclonal
drug interactions
pregnancy
breast feeding
fertility
drug evaluation, preclinical
Brentuximab Vedotin
Brentuximab Vedotin
brentuximab vedotin

---
Nous contacter.
27/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.